CRISPR Therapeutics
CRSP
CRSP
435 hedge funds and large institutions have $3.7B invested in CRISPR Therapeutics in 2022 Q3 according to their latest regulatory filings, with 58 funds opening new positions, 129 increasing their positions, 115 reducing their positions, and 50 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
1.06% more ownership
Funds ownership: 71.64% → 72.71% (+1.1%)
5% more call options, than puts
Call options by funds: $223M | Put options by funds: $213M
0% more funds holding
Funds holding: 434 → 435 (+1)
Holders
435
Holding in Top 10
8
Calls
$223M
Puts
$213M
Top Buyers
| 1 | +$48.9M | |
| 2 | +$44.3M | |
| 3 | +$34.5M | |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$18.9M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$17.9M |
Top Sellers
| 1 | -$119M | |
| 2 | -$97.4M | |
| 3 | -$25.3M | |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$21M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
-$20.9M |